Logo image of OTLK

OUTLOOK THERAPEUTICS INC (OTLK) Stock Fundamental Analysis

NASDAQ:OTLK - Nasdaq - US69012T3059 - Common Stock - Currency: USD

1.45  +0.08 (+5.84%)

After market: 1.44 -0.01 (-0.69%)

Fundamental Rating

0

Overall OTLK gets a fundamental rating of 0 out of 10. We evaluated OTLK against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of OTLK have multiple concerns. OTLK has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OTLK had negative earnings in the past year.
OTLK had a negative operating cash flow in the past year.
In the past 5 years OTLK always reported negative net income.
In the past 5 years OTLK always reported negative operating cash flow.
OTLK Yearly Net Income VS EBIT VS OCF VS FCFOTLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

OTLK's Return On Assets of -275.26% is on the low side compared to the rest of the industry. OTLK is outperformed by 93.66% of its industry peers.
Industry RankSector Rank
ROA -275.26%
ROE N/A
ROIC N/A
ROA(3y)-215.73%
ROA(5y)-221.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTLK Yearly ROA, ROE, ROICOTLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OTLK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTLK Yearly Profit, Operating, Gross MarginsOTLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

0

2. Health

2.1 Basic Checks

OTLK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OTLK Yearly Shares OutstandingOTLK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
OTLK Yearly Total Debt VS Total AssetsOTLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -61.27, we must say that OTLK is in the distress zone and has some risk of bankruptcy.
OTLK's Altman-Z score of -61.27 is on the low side compared to the rest of the industry. OTLK is outperformed by 94.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -61.27
ROIC/WACCN/A
WACCN/A
OTLK Yearly LT Debt VS Equity VS FCFOTLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

2.3 Liquidity

OTLK has a Current Ratio of 0.32. This is a bad value and indicates that OTLK is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.32, OTLK is doing worse than 94.54% of the companies in the same industry.
A Quick Ratio of 0.26 indicates that OTLK may have some problems paying its short term obligations.
OTLK's Quick ratio of 0.26 is on the low side compared to the rest of the industry. OTLK is outperformed by 95.25% of its industry peers.
Industry RankSector Rank
Current Ratio 0.32
Quick Ratio 0.26
OTLK Yearly Current Assets VS Current LiabilitesOTLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.50% over the past year.
EPS 1Y (TTM)77.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%190%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, OTLK will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.60% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.67%
EPS Next 2Y26.71%
EPS Next 3Y21.1%
EPS Next 5Y19.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OTLK Yearly Revenue VS EstimatesOTLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
OTLK Yearly EPS VS EstimatesOTLK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OTLK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OTLK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OTLK Price Earnings VS Forward Price EarningsOTLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTLK Per share dataOTLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as OTLK's earnings are expected to grow with 21.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.71%
EPS Next 3Y21.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OTLK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK (4/17/2025, 8:00:02 PM)

After market: 1.44 -0.01 (-0.69%)

1.45

+0.08 (+5.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-14 2025-02-14/bmo
Earnings (Next)05-14 2025-05-14/bmo
Inst Owners16.1%
Inst Owner Change-3.33%
Ins Owners0.24%
Ins Owner Change0%
Market Cap47.30M
Analysts83.33
Price Target10.71 (638.62%)
Short Float %14.83%
Short Ratio4.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)190.21%
Min EPS beat(2)189.34%
Max EPS beat(2)191.08%
EPS beat(4)3
Avg EPS beat(4)80.03%
Min EPS beat(4)-78.78%
Max EPS beat(4)191.08%
EPS beat(8)6
Avg EPS beat(8)45.06%
EPS beat(12)7
Avg EPS beat(12)22.73%
EPS beat(16)8
Avg EPS beat(16)11.95%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-67.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.54%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS0
BVpS-1.54
TBVpS-1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -275.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-215.73%
ROA(5y)-221.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.32
Quick Ratio 0.26
Altman-Z -61.27
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%190%
EPS Next Y6.67%
EPS Next 2Y26.71%
EPS Next 3Y21.1%
EPS Next 5Y19.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-73.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.53%
OCF growth 3YN/A
OCF growth 5YN/A